Evidence map›Paper›PMID 41730520›Full record

ReviewCirculation. Heart failure2026

Mitigating Risk of Kidney Dysfunction After Heart Transplantation and Therapeutic Approaches.

Ersilia M DeFilippis, Richard K Cheng, Elena M Donald, Shannon M Dunlay, Lorraine S Evangelista, Forum Kamdar, Prateeti Khazanie, Selma F Mohammed, Ana P Rossi, Harriette G C Van Spall and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Circulation. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Impact of SGLT2 Inhibitors on Clinical Outcomes in Patients with Diabetes Mellitus Following Heart Transplantation: A Meta-analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ersilia M DeFilippisDepartment of Medicine, Center for Advanced Cardiac Care, Division of Cardiology, New York Presbyterian-Columbia University Irving Medical Center (E.M. DeFilippis, E.M. Donald).ORCID 0000-0002-0493-1326
Richard K ChengDivision of Cardiology, University of Washington, Seattle, WA (R.K.C.).
Elena M DonaldDepartment of Medicine, Center for Advanced Cardiac Care, Division of Cardiology, New York Presbyterian-Columbia University Irving Medical Center (E.M. DeFilippis, E.M. Donald).ORCID 0000-0002-2232-5688
Shannon M DunlayDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (S.M.D.).ORCID 0000-0001-5145-7420
Lorraine S EvangelistaSue & Bill Gross School of Nursing, University of California Irvine (L.S.E.).ORCID 0000-0003-1708-4186
Forum KamdarDivision of Cardiology, University of Minnesota, Minneapolis (F.K.).ORCID 0000-0003-3218-0467
Prateeti KhazanieDivision of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (P.K.).ORCID 0000-0001-8959-1609
Selma F MohammedDivision of Cardiology, Creighton University Medical Center, Omaha, NE (S.F.M.).ORCID 0000-0003-3553-2720
Ana P RossiPiedmont Transplant Institute, Atlanta, GA (A.P.R.).ORCID 0009-0004-1479-3571
Harriette G C Van SpallFaculty of Health Sciences, McMaster University, Hamilton, ON, Canada (H.G.C.V.S.).ORCID 0000-0002-8370-4569
Aradhana VermaDivision of Cardiology, Stanford University, Palo Alto, CA (A.V.).ORCID 0000-0002-8877-2325
Khadijah BreathettDivision of Cardiovascular Medicine, Krannert Cardiovascular Research Center, Indiana University School of Medicine, Indianapolis (K.B.).ORCID 0000-0001-5397-6419

Funding

Examining the Effects of High Protein Diet on Outcomes in Heart Failure PatientsR01HL093466 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EVANGELISTA, LORRAINE S · 2009 to 2013
$1.9M
Fitness Intensive Therapy (Get FIT) to Promote Healthy Living in Older AdultsR21AG053162 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI EVANGELISTA, LORRAINE S · 2018 to 2019
$425k
NHLBI NIH HHS R01 HL093466NIA NIH HHS R21 AG053162
6 · The paper itself

Abstract

Kidney dysfunction after heart transplantation (HT) is associated with significant morbidity and mortality. Recipient and perioperative factors may all influence the risk of kidney injury. Furthermore, data suggest that the incidence of kidney dysfunction, both acute and chronic, is increasing after the implementation of the United States' 2018 allocation system due to increasing use of temporary mechanical circulatory support and changing recipient characteristics. While data are robust regarding nephroprotective therapies such as renin-angiotensin-aldosterone system inhibition and SGLT2i (sodium-glucose cotransporter 2 inhibitors) to minimize the progression of chronic kidney disease in patients with heart failure, data in HT recipients are beginning to emerge. This state-of-the-art review will critically examine the existing literature regarding the epidemiology of kidney dysfunction after HT, mitigation strategies for acute kidney injury and chronic kidney disease, including pharmacotherapeutics, the need for kidney transplantation after HT, and practical next steps for the larger HT community.

Indexed as

Acute Kidney InjuryHeart FailureHeart TransplantationRenal Insufficiency, ChronicHumansKidney TransplantationRisk Factorsdialysisheart failureheart transplantationkidney diseasekidney transplantation

Identifiers

PMID41730520
PMCPMC13335661

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.